Abstract
The clinical response to two doses of sustained-release nifedipine was as sessed during a double-blind, randomized, placebo-controlled trial in 22 pa tients with primary Raynaud's phenomenon. Nifedipine at doses of 20 mg and 40 mg daily reduced the mean number of attacks by 40% compared with pla cebo with no significant differences between the two doses in the number of attacks or their severity. Unwanted effects were more common and more per sistent with the higher dose of nifedipine. Fingertip vibrotactile thresholds mea sured at 31.5 and 125 Hz were unchanged by treatment with nifedipine. There was, however, a correlation between the pretreatment threshold at 125 Hz and the response to treatment with nifedipine, the most favorable responses occur ring in patients with the lowest thresholds.
Get full access to this article
View all access options for this article.